First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer

被引：0
作者：
Hossein Taghizadeh
Matthias Unseld
Andreas Schmiderer
Angela Djanani
Klaus Wilthoner
Dieter Buchinger
Gerald W. Prager
机构：
[1] Medical University of Vienna,Clinical Division of Oncology, Department of Medicine I
[2] Comprehensive Cancer Center,Clinical Division of Gastroenterology, Hepatology and Metabolism, Department of Internal Medicine I
[3] Medical University Innsbruck,Clinical Division of Oncology, Department of Medicine I
[4] Salzkammergut Klinikum,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2020年 / 86卷
关键词：
Biliary tract cancer; Chemotherapy; Nanoliposomal irinotecan; Progression-free survival; Overall survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：109 / 115
页数：6
相关论文
共 50 条
  • [31] Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)
    Souglakos, J.
    Ziras, N.
    Kakolyris, S.
    Boukovinas, I.
    Kentepozidis, N.
    Makrantonakis, P.
    Xynogalos, S.
    Christophyllakis, C. H.
    Kouroussis, C. H.
    Vamvakas, L.
    Georgoulias, V.
    Polyzos, A.
    BRITISH JOURNAL OF CANCER, 2012, 106 (03) : 453 - 459
  • [32] Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial
    Michael Gubanski
    Anders Johnsson
    Eva Fernebro
    Lianna Kadar
    Ingegerd Karlberg
    Petra Flygare
    Åke Berglund
    Bengt Glimelius
    Pehr A. Lind
    Gastric Cancer, 2010, 13 : 155 - 161
  • [33] Efficacy of concurrent chemoradiotherapy with 5-fluorouracil or gemcitabine in locally advanced biliary tract cancer
    Seung Woo Yi
    Dae Ryong Kang
    Kyung Sik Kim
    Mi Suk Park
    Jinsil Seong
    Jeong Youp Park
    Seung Min Bang
    Si Young Song
    Jae Bock Chung
    Seung Woo Park
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 191 - 198
  • [34] Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial
    Gubanski, Michael
    Johnsson, Anders
    Fernebro, Eva
    Kadar, Lianna
    Karlberg, Ingegerd
    Flygare, Petra
    Berglund, Ake
    Glimelius, Bengt
    Lind, Pehr A.
    GASTRIC CANCER, 2010, 13 (03) : 155 - 161
  • [35] Treatment with a nonanthracycline regimen in advanced breast cancer - Vinorelbine, cyclophosphamide, and 5-fluorouracil with folinic acid
    Turpin, F
    Lluch, A
    Closen, MH
    Gruia, G
    Llombart, A
    Fernandez, R
    Delgado, FM
    Biville, F
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1999, 22 (02): : 196 - 198
  • [36] Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer
    Shigeta, Kohei
    Hasegawa, Hirotoshi
    Okabayashi, Koji
    Tsuruta, Masashi
    Ishii, Yoshiyuki
    Endo, Takashi
    Ochiai, Hiroki
    Kondo, Takayuki
    Kitagawa, Yuko
    INTERNATIONAL JOURNAL OF CANCER, 2016, 139 (04) : 946 - 954
  • [37] PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer
    Chibaudel, Benoist
    Maindrault-Goebel, Frederique
    Bachet, Jean-Baptiste
    Louvet, Christophe
    Khalil, Ahmed
    Dupuis, Olivier
    Hammel, Pascal
    Garcia, Marie-Line
    Bennamoun, Mostefa
    Brusquant, David
    Tournigand, Christophe
    Andre, Thierry
    Arbaud, Claire
    Larsen, Annette K.
    Wang, Yi-Wen
    Yeh, C. Grace
    Bonnetain, Franck
    de Gramont, Aimery
    CANCER MEDICINE, 2016, 5 (04): : 676 - 683
  • [38] Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin
    Hubner, Richard A.
    Cubillo, Antonio
    Blanc, Jean-Frederic
    Melisi, Davide
    Von Hoff, Daniel D.
    Wang-Gillam, Andrea
    Chen, Li-Tzong
    Becker, Claus
    Mamlouk, Khalid
    Belanger, Bruce
    Yang, Yoojung
    de Jong, Floris A.
    Siveke, Jens T.
    EUROPEAN JOURNAL OF CANCER, 2019, 106 : 24 - 33
  • [39] Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study
    Moehler, M.
    Mueller, A.
    Trarbach, T.
    Lordick, F.
    Seufferlein, T.
    Kubicka, S.
    Geissler, M.
    Schwarz, S.
    Galle, P. R.
    Kanzler, S.
    ANNALS OF ONCOLOGY, 2011, 22 (06) : 1358 - 1366
  • [40] Outpatient therapy with irinotecan and low-dose cisplatin for metastatic colorectal cancer resistant to 5-fluorouracil
    Shimada, S
    Yagi, Y
    Shiomori, K
    Kuramoto, M
    Aoki, N
    Ogawa, M
    ONCOLOGY REPORTS, 2002, 9 (04) : 783 - 787
12345